<DOC>
	<DOCNO>NCT01237054</DOCNO>
	<brief_summary>Background : - Recent study show premalignant condition monoclonal gammopathy undetermined significance ( MGUS ) smolder multiple myeloma ( SMM ) high risk progress multiple myeloma ( MM ) . There currently know effective treatment prevent MGUS SMM develop MM , know test determine whether individual MGUS SMM develop MM . Researchers investigate new improve imaging technique may able good detect progression MGUS SMM MM . Objectives : - To compare result three image technique individual MGUS , SMM , MM . - To correlate information image study establish clinical marker progression MGUS/SMM MM . Eligibility : - Individuals least 18 year age diagnose monoclonal gammopathy undetermined significance , smolder multiple myeloma , multiple myeloma . Design : - Participants screen physical examination medical history , provide baseline blood , urine , bone marrow sample begin image study . - Participants three image study separate day : standard 18-fludeoxyglucose positron emission tomography/computed tomography scan ( 18-FDG PET/CT ) , PET/CT scan experimental sodium fluoride-based drug ( 18-NaF PET/CT ) , dynamic contrast-enhanced magnetic resonance imaging ( DCE-MRI ) . - Participants closely monitor scan , provide additional blood sample scan . - Participants may provide additional blood , urine , tissue , bone marrow sample optional research study .</brief_summary>
	<brief_title>Imaging MGUS , SMM MM</brief_title>
	<detailed_description>Background : - Multiple myeloma ( MM ) plasma cell neoplasm median survival 3-4 year . - Monoclonal gammopathy undetermined significance ( MGUS ) smolder myeloma ( SMM ) premalignant plasma cell proliferative disorder characterize elevated monoclonal protein bone marrow plasma cell . MGUS affect 3.2 % Caucasians age 50 1 % annual risk progression MM . Approximately 3000 case SMM diagnose annually 10 % annual risk progression MM . - Currently , possible predict patient progress MM . - Novel image modality ( FDG-PET , 18-NaF PET DCE-MRI ) may improve ability predict patient high risk progression . Objectives : - To compare result image modality ( 18-NaF PET/CT , 18-FDG PET/CT , DCE-MRI ) patient MGUS , SMM , MM . - To correlate imaging study establish clinical marker progression MGUS/SMM MM , include serum M-protein , percentage plasma cell bone marrow , serum free light-chain abnormality immunoparesis , ratio normal/abnormal plasma cell bone marrow flow cytometry . Eligibility : - A confirmed diagnosis MGUS , SMM MM ( base IMWG ( International Myeloma Working Group ) diagnostic criterion ) - Age great equal 18 year - ECOG ( Eastern Cooperative Oncology Group ) performance status range 0-2 Design : - This cross-sectional pilot study patient MGUS , SMM MM . - Following initial evaluation confirmation diagnosis , baseline study include skeletal survey do . - Subsequently 18-NaF PET/CT , 18-FDG PET/CT DCE-MRI image do patient . - 10 MGUS , 11 SMM 10 MM patient enrol protocol . - Patients may donate cellular product tissue appropriate research purpose . - Almost MGUS SMM patient follow clinically part 10-C-0096 : Natural History Study Monoclonal Gammopathy Undetermined Significance ( MGUS ) Smoldering Myeloma ( SMM ) .</detailed_description>
	<mesh_term>Multiple Myeloma</mesh_term>
	<mesh_term>Neoplasms , Plasma Cell</mesh_term>
	<mesh_term>Paraproteinemias</mesh_term>
	<mesh_term>Monoclonal Gammopathy Undetermined Significance</mesh_term>
	<mesh_term>Fluorodeoxyglucose F18</mesh_term>
	<criteria>INCLUSION CRITERIA : Diagnosis MGUS , SMM MM make accordance clinical diagnostic criterion set forth International Myeloma Working Group.2 . The diagnosis confirm laboratory test , serum/urine protein electrophoresis , immunofixation lightchain assay , skeletal survey , immunohistochemistry analysis bone marrow biopsy , combination . Age great equal 18 year . ECOG ( Eastern Cooperative Oncology Group ) performance status 02 . The patient must competent sign inform consent form . Creatinine le 2.5 ULN eGFR ( estimate glomerular filtration rate ) great 30 EXCLUSION CRITERIA : A medical history malignancy ( apart basal cell carcinoma skin situ cervical carcinoma ; also , MM patient include MM ) except patient free symptom without active therapy least previous 5 year . Female subject pregnant breastfeeding .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2015</verification_date>
	<keyword>18-FDG PET/CT</keyword>
	<keyword>Abnormal Plasma Cells</keyword>
	<keyword>Serum Free Light-Chain Abnormality</keyword>
	<keyword>Serum M-Protein</keyword>
	<keyword>DCE-MRI</keyword>
	<keyword>Multiple Myeloma</keyword>
	<keyword>Smoldering Multiple Myeloma</keyword>
	<keyword>SMM</keyword>
	<keyword>MM</keyword>
</DOC>